Compare

InMode/$INMD

1D1W1M3M6MYTD1Y5YMAX

About InMode

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
Ticker
$INMD
Sector
Health
Primary listing
NASDAQ
Employees
660
Headquarters
Yokne'am, Israel
Website
www.inmodemd.com

InMode Metrics

BasicAdvanced
$766M
10.95
$1.22
1.87
-

What the Analysts think about InMode

Analyst ratings (Buy, Hold, Sell) for InMode stock.
Analyst projections of the future price of InMode stock.

Bulls say / Bears say

Sales may be finding a floor: first-quarter revenue rose 5% year on year and second-quarter revenue held steady at $95.6 million. Consumables and service grew 13% in Q2, while Asia reached a quarterly revenue record. (InMode, InMode)
The balance sheet provides resilience and room to return capital: InMode reported $501.1 million in cash, marketable securities and short-term deposits at the end of June. It also completed an $87.8 million buyback of 6.38 million shares. (InMode)
Morpheus8 Cool, launched for the expandable Morpheus8MAX platform, refreshes a flagship product with added comfort and treatment controls. If clinics adopt it, the upgrade could support sales beyond a simple recovery in existing device demand. (InMode)
The recovery remains tentative: Q2 revenue was flat year on year, and management expects Q3 revenue of $91.8–$92.0 million while keeping full-year revenue guidance at $365–$375 million. That outlook points to stabilisation, not a clear return to growth. (InMode, InMode)
Profitability is falling faster than sales: Q2 gross margin dropped to 75% from 80%, operating margin fell to 13% from 24%, and net income declined to $17.1 million from $26.7 million. Management expects the cost and mix pressures to continue for the foreseeable future. (InMode)
Governance and communication risks could weigh on confidence: InMode says a special committee is still reviewing a proposal and has paused earnings calls and investor meetings during the process. Activist Steel Partners has criticised the board over the curtailed communication and its oversight. (InMode, Steel Partners Holdings)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.

InMode Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

InMode Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing InMode

Funds
Fund name
Fund size
$INMD weighting
iShares Ageing Population$AGED
$953M0.07%
iShares Ageing Population£AGES
$953M0.07%
iShares Ageing Population€AGED
$903M0.07%
Xtrackers MSCI World Small Cap$XSWC
$183M0.01%
iShares MSCI World Small Cap€IUSN
$9B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.